Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature emphasized mechanistic immunoinflammation and translational therapeutic targets, resolution-phase analgesia, and procedure-focused respiratory optimization. A high-impact mechanistic study defined an EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 circuit driving pathological NETosis in sepsis, providing druggable targets. Protectin DX (a specialized proresolving mediator) showed GPR37-dependent resolution analgesia in preclinical models, and an IPD meta-analysis establishe
Summary
This week’s anesthesiology literature emphasized mechanistic immunoinflammation and translational therapeutic targets, resolution-phase analgesia, and procedure-focused respiratory optimization. A high-impact mechanistic study defined an EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 circuit driving pathological NETosis in sepsis, providing druggable targets. Protectin DX (a specialized proresolving mediator) showed GPR37-dependent resolution analgesia in preclinical models, and an IPD meta-analysis established high-flow nasal cannula (≥45 L/min) as superior for preventing desaturation during bronchoscopy.
Selected Articles
1. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.
This translational mechanistic study identifies an EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 signaling circuit within neutrophils that drives pathological NETosis in sepsis. Neutrophil-specific EGFR deletion reduced cytokine storm, NET formation, tissue injury, and improved survival in mouse models; recombinant PGLYRP1 reversed protection, confirming pathway centrality.
Impact: Defines a druggable neutrophil-intrinsic circuit linking receptor signaling to NETosis, offering concrete molecular targets (EGFR, MAPK14, PGLYRP1/TREM-1) to mitigate neutrophil-driven immunopathology in sepsis.
Clinical Implications: Supports development and prioritization of therapeutics targeting EGFR–MAPK14–PGLYRP1–TREM1 axis (e.g., EGFR modulators, TREM-1 inhibitors) and using neutrophil EGFR/PGLYRP1 expression for patient stratification in sepsis trials.
Key Findings
- EGFR is upregulated in neutrophils from sepsis patients and correlates with severity.
- Neutrophil-specific EGFR knockout improves survival and reduces cytokine storm, tissue injury, and NET formation in polymicrobial sepsis models.
- EGFR recruits MAPK14 to phosphorylate CEBPβ, driving PGLYRP1 transcription; PGLYRP1 amplifies NETosis via autocrine TREM-1 signaling.
- Recombinant PGLYRP1 or forced CEBPβ overexpression reverses EGFR deficiency protection, confirming axis centrality.
2. Protectin DX resolves fracture-induced postoperative pain in mice via neuronal signaling and GPR37-activated macrophage efferocytosis.
Protectin DX (PDX), a specialized proresolving mediator, shortened and resolved postoperative fracture pain in mice more effectively than PD1/DHA, steroids, or meloxicam. Effects required GPR37, enhanced macrophage efferocytosis via calcium signaling, and rapidly dampened nociceptor activity, suggesting a resolution-focused analgesic mechanism.
Impact: Introduces a translational, resolution-centric analgesic mechanism (PDX → GPR37 → macrophage efferocytosis + nociceptor suppression) that shortens pain duration instead of simply masking pain, pointing to a new class of perioperative analgesics.
Clinical Implications: Encourages development of PDX analogs and GPR37-targeting agents for perioperative analgesia; such agents could shorten pain duration and avoid some drawbacks of steroids/NSAIDs. Early-phase PK/safety studies and biomarker-driven stratification (GPR37) are next steps.
Key Findings
- IV PDX (100 ng/mouse) alleviated early and late phases of fracture-induced postoperative pain and shortened pain duration.
- PDX outperformed PD1/DHA, steroids, and meloxicam; analgesia was absent in Gpr37−/− mice.
- PDX binds GPR37, induces macrophage calcium responses and efferocytosis, and suppresses nociceptor C-fiber and DRG calcium responses.
3. High flow nasal cannula versus conventional oxygen therapy during bronchoscopy: A systematic review and individual participant data meta-analysis.
A meta-analysis of 17 RCTs (n=3,116) with IPD from six trials found HFNC significantly reduced desaturation, procedural interruptions, respiratory support escalation, and airway interventions during bronchoscopy versus conventional oxygen. Exploratory IPD analyses identified greater relative benefit at lower BMI and lower baseline respiratory/heart rates and indicated flows ≥45 L/min further reduce desaturation risk.
Impact: Provides high-level, practice-relevant evidence (with IPD) establishing HFNC as superior for bronchoscopy oxygenation and identifying actionable parameters (≥45 L/min) and patient subgroups that derive greatest benefit.
Clinical Implications: Recommend HFNC as first-line oxygenation for adult bronchoscopy when available, targeting flows ≥45 L/min where tolerated; prioritize HFNC for patients likely to derive greater benefit (lower BMI, lower baseline respiratory/heart rates) and maintain quantitative monitoring.
Key Findings
- HFNC reduced desaturation vs conventional oxygen during bronchoscopy (OR 0.23, 95% CI 0.15–0.34).
- HFNC decreased procedure interruption, escalation of respiratory support, and airway interventions.
- Flows ≥45 L/min were associated with additional reduction in desaturation risk; IPD suggested larger relative benefit at lower BMI and lower baseline respiratory/heart rates.